For a study, researchers sought to survey the well-being and viability of the Preserflo Microshunt (PSM) for the therapy of open point glaucoma with 0.2 mg/mL mitomycin C, either alone or in a mix with a waterfall medical process. A review, open-name investigation of 64 eyes with essential open point glaucoma that went through PSM inculcation was followed up for no less than 9 months. The achievement was characterized as IOP 6-17 mm Hg and a reduction of something like 20%, completed without hypotensive medicine and passed with directions. The range of antagonistic times surveyed security. Additional endpoints include average hypotensive drugs, visual keenness, needling speed, and careful shaping. A total of 51 eyes went through PSM alone and 13 through PSM+phacoemulsification. In the general populace of the research, the average IOP reduced from 22.03±0.7 mm Hg at the gauge to somewhere between 12.7±0.4 mm Hg at the last visit, P<0.0001 (average development: 11±1.4 mo). The IOP was altogether diminished in the 2 gatherings (P<0.0001). The visual hypotensive drug was diminished importantly from 2.7±0.7 to 0.2±0.5 (P<0.0001). No massive differences were determined in IOP-bringing down drugs between gatherings (PSM alone, 0.2±0.08; PSM+phacoemulsification, 0.1±0.1; P=0.2). At the last visit, 70.3% were considered a complete achievement and 12.5% as a thorough goal. The most known unfavorable time was clinical hypotony (7.8%), trailed by hyphema (4.7%) and front chamber reorganization (1.6%). In general, 1.6% expected needling and 15.6% careful updates to establish the stream again. Glaucoma medical process with the PSM and mitomycin C was essential and determined safely temporarily, either alone or in the mix with waterfall medical process, and might have been determined as a careful choice for bringing down IOP in essential open point glaucoma.

Source: journals.lww.com/glaucomajournal/Fulltext/2022/07000/Efficacy_and_Safety_of_the_Preserflo_Microshunt.10.aspx